Theramex Announces Completion of its Acquisition of the Femoston® and Duphaston® Products in Europe (ex-UK) from Viatris. 

We are pleased to announce that Theramex has completed its acquisition of the Femoston® and Duphaston® products in Europe (ex-UK) from Viatris. These products will complement our existing Menopause portfolio, ensuring women have a variety of treatments across Europe. Theramex’s acquisition of the UK rights remains subject to regulatory approval and until then Viatris retains the rights to the products in the UK.

This acquisition represents a substantial investment into our portfolio. It further demonstrates the commitment Theramex has to Women’s Health, and the support of our ownership Carlyle and PAI in delivering on this vision. These products not only provide Theramex with a broader range of HRT options but will enable us to expand our reach and positively impact the lives of more women.

We remain focused on our commitment to women’s health and the improvement of our patients’ access to quality treatments and resources, empowering women to take charge of their health at different stages of life.